Dr. Martin Barkin has been appointed executive vice presidentof Deprenyl Research Ltd. and is slated to be appointedpresident to succeed James P. Doherty, who will become vicechairman. The Toronto company (NASDAQ:DEPLF) said Barkin,formerly deputy minister of health for Ontario, also will benominated as a director. Deprenyl is developing productslargely devoted to Parkinson's and other neurological diseases.
Cephalon Inc. of West Chester, Pa., has named Bruce A. Peacockexecutive vice president and chief financial officer. NicholasLandekie was named director of business development.Peacock was senior vice president and chief financial officer atCentocor Inc.; Landekie was senior manager of businessplanning at Bristol-Myers Squibb. Cephalon (NASDAQ:CEPH) isfocused on therapeutics for stroke and neurodegenerativedisorders.
Thomas G. Wiggans has been named chief operating officer atCytoTherapeutics. Wiggans had been general manager ofSerono Laboratories UK. CytoTherapeutics (formerly CellularTransplants Inc.) of Providence, R.I., is developing patentablemembrane products to treat a variety of chronic and disablingdiseases.
Interneuron Pharmaceuticals Inc. has named Dr. Bobby W.Sandage Jr. vice president for medical and scientific affairs. Inaddition, John E. Mattern has been named chief financialofficer, and Lee. J. Schroeder has been added to the Lexington,Mass., company's board. Sandage managed productdevelopment at Du Pont Merck. Mattern had been vicepresident of finance and administration at Serono LaboratoriesInc., and Schroeder was president of Fox Meyer Drug Co.Interneuron (NASDAQ:IPIC) develops treatments for centralnervous system disorders.
Donald H. Picker, Ph.D., has been named senior vice president ofresearch and development at Genta Inc. The company alsonamed Howard Sampson vice president of finance andcontroller. Picker was vice president of biomedical research atJohnson Matthey Inc. Sampson was a financial and accountingconsultant to Genta and other companies. Genta(NASDAQ:GNTA) of San Diego is developing treatments forinflammatory, cardiovascular and viral diseases and cancer.
OraVax Inc., a privately held biopharmaceutical company, hasnamed Dr. Thomas P. Monath vice president of research anddevelopment and chairman of its scientific advisory board. Hewill be leaving his position as chief of the virology division ofthe U.S. Army Medical Research Institute of InfectiousDiseases at Fort Detrick, Md. OraVax of Cambridge, Mass.,is focused on the prevention and treatment of humaninfectious diseases.
Kathryn R. Bloom has been named director of communicationsat Biogen Inc. (NASDAQ:BGEN) of Cambridge, Mass. She wasdirector of pharmaceutical and research communications atBristol-Myers Squibb.
Roland M. Hendrickson has been named to the board ofInnoVet Inc. He was president of Pfizer Inc.'s agriculturaldivision. InnoVet (NASDAQ:IVET) of Boca Raton, Fla., isdeveloping human and animal health, and agriculturalproducts.
Liposome Technology Inc. (NASDAQ:LTIZ) of Menlo Park, Calif.,has appointed Melody Anderson associate director of clinicalresearch, and Peter Working, Ph.D., director of pharmacologyand toxicology. Anderson was manager of medical affairs atXoma Corp. Working had been senior toxicologist at GenentechInc.
The Liposome Co. Inc. (NASDAQ:LIPO) of Princeton, N.J., hasappointed Karl E. Arfors executive director of biologicalsciences. Arfors was president and chief executive of the LaJolla Institute for Experimental Medicine and director ofexplorative research for Pharmacia Experimental Medicine ofLa Jolla, Calif.
Gerald Walsh has been named executive director of biologicalsciences for BioCryst Pharmaceuticals Inc. of Birmingham, Ala.Walsh was director of research and development at SoloPakLaboratories, an American affiliate of the Britishpharmaceutical company Smith & Nephew Ltd. BioCryst isdesigning inhibitors for a number of diseases.
Boston Biomedica Inc. of West Bridgewater, Mass., has namedRonald V. DiPaolo director of operations. He was vice presidentand general manager of the Biomedical Products Division ofCollaborative Research Inc. Boston Biomedica is a manufacturerand supplier of AIDS, hepatitis and other infectious diseasediagnostic reagents.
Biomerica Inc. of Newport Beach, Calif., has appointed DougMiller president and chief operating officer of its LancerOrthodontics Inc. (NASDAQ:LANZ). Miller was previouslydirector of worldwide market development for the "A" Co., aJohnson & Johnson company. Biomerica (NASDAQ: BMRA) ismedical diagnostic company.
(c) 1997 American Health Consultants. All rights reserved.